Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phenlarmide pharmacokinetics in healthy Chinese volunteers
NCT04164121Phase 1Completed
- Sponsor
- Yiling Pharmaceutical
- Start
- Dec 2019
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of phenlarmide in Parkinson's disease (PD) (6 arms), sponsored by Yiling Pharmaceutical. Primary endpoints: Tolerance evaluation index, Time to Maximum Plasma Concentration (Tmax) and 12 more. Started Dec 2019; status: completed.
02
Drugs
phenlarmide
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT04164121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04164121.